智通财经APP讯，石药集团(01093)发布公告，本集团开发的化药1类新药高选择性PDE4B抑制剂(SYH2059吸入粉雾剂)(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品亦已于2026 年3月获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。
该产品是本集团一款全新的、具有完全自主知识产权的高活性与高选择性磷酸二酯酶 4B(PDE4B)抑制剂。本次获得临床试验批准的剂型为吸入粉雾剂。临床前研究显示，该产品可明显提高药物肺部浓度，降低系统暴露，从而降低胃肠道副作用，在疾病动物模型上的药效明显优于现有药物，且具有良好的药代动力学特征和较高的安全窗口。
本次获批的临床适应症为间质性肺疾病。目前市场上用于治疗该类疾病的药物为数不多，且患者治疗获益有限，该产品有望成为该类疾病的有效治疗药物，具有较大临床开发价值。该产品获得临床试验批准，是本集团高端创新吸入技术平台的重要成果，为管线内后续创新吸入制剂的开发奠定了良好基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.